ZNTL/ 07/17/2026 · 12:00 PM Zentalis Pharmaceuticals Gets Outperform Rating from Mizuho on Azenosertib Potential Analyst highlights 75% upside potential ahead of key Phase 2 DENALI data readout for lead drug azenosertib.
